RNTX Home Investment Highlights Valuation & Metrics Price Chart Why The Stock Moved Return vs. Risk About RNTX Interactive Breakdown Better Bets vs. RNTX Peer Outperformance Latest Trefis Analyses Trade Ideas More From Trefis Peer Comparisons FDIC Bank Data FDA Approved Drugs Data Clinical Pipeline Financials Segment Financials Price Behavior Short Interest Earnings Returns History SEC Filings Forward Guidance Insider Activity Investor Activity (13F) Trade Sentinel Investor Videos Industry Resource Links External Quote Links

    Rein Therapeutics (RNTX)

    Market Price (9/21/2026): $0.7925 | Market Cap: $53.2 MilSector: Health Care | Industry: Biotechnology

    Rein Therapeutics (RNTX)

    Market Price (9/21/2026): $0.7925
    Market Cap: $53.2 Mil
    Sector: Health Care
    Industry: Biotechnology

    Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

    0

    Cash is significant % of market cap
    Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -76%

    Megatrend and thematic drivers
    Megatrends include Biotechnology & Genomics, and Precision Medicine. Themes include Gene Editing & Therapy, Biopharmaceutical R&D, Show more.

    Weak multi-year price returns
    2Y Excs Rtn is -107%, 3Y Excs Rtn is -121%

    Penny stock
    Mkt Price is 0.8

    Very low revenue
    Rev LTMTotal Revenue or Sales, Last Twelve Months is 0

    Not profitable at operating income level
    Op Inc LTMOperating Income, Last Twelve Months is -21 Mil

    Yield minus risk free rate is negative
    ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -97%

    Key risks
    RNTX key risks include [1] substantial 'going concern' doubt due to insufficient capital to fund its LTI-03 and LTI-01 candidates, Show more.

    0 Cash is significant % of market cap
    Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -76%
    1 Megatrend and thematic drivers
    Megatrends include Biotechnology & Genomics, and Precision Medicine. Themes include Gene Editing & Therapy, Biopharmaceutical R&D, Show more.
    2 Weak multi-year price returns
    2Y Excs Rtn is -107%, 3Y Excs Rtn is -121%
    3 Penny stock
    Mkt Price is 0.8
    4 Very low revenue
    Rev LTMTotal Revenue or Sales, Last Twelve Months is 0
    5 Not profitable at operating income level
    Op Inc LTMOperating Income, Last Twelve Months is -21 Mil
    6 Yield minus risk free rate is negative
    ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -97%
    7 Key risks
    RNTX key risks include [1] substantial 'going concern' doubt due to insufficient capital to fund its LTI-03 and LTI-01 candidates, Show more.

    RNTX in ETFs

    Weight = RNTX's share of each fund

    VTI0.00%

    Valuation & Metrics

    FYE: 12/31RNTX [1]S&P 500 [2]
    REVENUE GROWTH
    LTM Revenue [3]$0.0 Mil—
    FY 2026 Sales$69.8 Mil—
    FY 2027 Sales$127.7 Mil—
    FY 2026 Sales Growth——
    FY 2027 Sales Growth83.0%12.9%
    EARNINGS
    LTM Net Income (GAAP) [3]$-49.8 Mil—
    FY 2026 Net Income (Non-GAAP)$-11.7 Mil—
    FY 2027 Net Income (Non-GAAP)$-11.8 Mil—
    FY 2027 Net Income Growth—18.1%
    FY 2026 EPS (Non-GAAP)$-0.46—
    FY 2027 EPS (Non-GAAP)$-0.47—
    FY 2027 EPS Growth——
    VALUATION
    FY 2026 P/S0.81.6
    FY 2027 P/S0.4—
    FY 2026 P/E—7.4
    FY 2027 P/E——

    [1] RNTX forward figures are analyst consensus for the next two fiscal years (fiscal year end 12/31). Net Income and EPS are non-GAAP (adjusted) consensus. P/S and P/E divide the current market cap by the consensus figure.
    [2] S&P 500 figures are the SPY ETF's holdings-weighted forward aggregate. P/S and P/E reflect FY1/FY2 consensus blended to the 12-month window ending 9/30/27 (~one year forward), shown when ≥90% of index weight has estimates. Growth is the aggregate next-fiscal-year vs current-fiscal-year (FY1→FY2) change. Index-level dollar Sales, Net Income and EPS are not applicable.
    [3] LTM = reported trailing-twelve-month actuals (GAAP).
    null

    AI Analysis | Feedback

    MetricValueDateSource
    Number of Drug Candidates in Pipeline311032025Link
    Number of Clinical Trials111032025Link
    Target Patient Enrollment for RENEW Phase 2 Trial12011032025Link
    Number of U.S. Clinical Trial Sites for RENEW Phase 2 Trial2011032025Link
    Number of Global Clinical Trial Sites for RENEW Phase 2 Trial3011032025Link
    Number of Patents Granted for LTI-0324232025Link

    Price Chart

    null
    Upcoming
    11/13/2026Earnings ReleaseRev: -
    EPS: -

    Why The Stock Moved

    Qualitative Assessment

    AI Analysis | Feedback

    Updated on 9/17/2026

    Rein Therapeutics (RNTX) stock has lost about 30% since 5/31/2026 because of the following key factors:

    1. Significant Share Dilution from Public Offering.

    Rein Therapeutics completed an underwritten public offering in May 2026, selling 57.5 million shares at $1.00 per share, which generated gross proceeds of $57.5 million. This substantial increase in the number of outstanding shares likely diluted existing shareholder value and contributed to downward pressure on the stock price.

    2. Continued Operating Losses and Lack of Revenue.

    For the fiscal second quarter ended June 30, 2026, Rein Therapeutics reported a net loss of $6.4 million, contributing to an accumulated deficit of $413.5 million as of the same date. The company generated no revenue during this period, which is typical for a clinical-stage biopharmaceutical company but highlights ongoing expenses without product sales.

    Show more
    Updated on 9/17/2026

    Rein Therapeutics (RNTX) stock has lost about 30% since 5/31/2026 because of the following key factors:

    1. Significant Share Dilution from Public Offering.

    Rein Therapeutics completed an underwritten public offering in May 2026, selling 57.5 million shares at $1.00 per share, which generated gross proceeds of $57.5 million. This substantial increase in the number of outstanding shares likely diluted existing shareholder value and contributed to downward pressure on the stock price.

    2. Continued Operating Losses and Lack of Revenue.

    For the fiscal second quarter ended June 30, 2026, Rein Therapeutics reported a net loss of $6.4 million, contributing to an accumulated deficit of $413.5 million as of the same date. The company generated no revenue during this period, which is typical for a clinical-stage biopharmaceutical company but highlights ongoing expenses without product sales.

    3. Nasdaq Delisting Warning.

    On August 21, 2026, Rein Therapeutics received a notice from Nasdaq indicating non-compliance with its minimum bid price rule, as the common stock's closing bid price had fallen below $1.00 for 30 consecutive trading days. The company has until February 17, 2027, to regain compliance, and this delisting risk introduces significant uncertainty and negatively impacts investor confidence.

    4. Uncertainty Regarding Phase 2 Trial Data Timeline.

    While Rein Therapeutics announced the Phase 2 RENEW trial for LTI-03 was fully enrolling across five countries by July 21, 2026, and reported exceeding 25% enrollment by August 14, 2026, a September 8, 2026, report indicated that Phase 2 results might not be available in the latter half of 2026 as initially anticipated. This potential delay in reporting critical clinical data for its lead candidate for idiopathic pulmonary fibrosis (IPF) could be a significant concern for investors in a development-stage biotech company.

    Show less
    Holding a concentrated position? Know your true downside before the momentum shifts.
    Protect Your Wealth →

    Stock Movement Drivers

    Fundamental Drivers

    The -27.9% change in RNTX stock from 5/31/2026 to 9/20/2026 was primarily driven by a -54.8% change in the company's Shares Outstanding (Mil).
    (LTM values as of)53120269202026Change
    Stock Price ($)1.110.80-27.9%
    Change Contribution By: 
    Total Revenues ($ Mil)000.0%
    P/S Multiple∞∞0.0%
    Shares Outstanding (Mil)3067-54.8%
    Cumulative Contribution0.0%

    LTM = Last Twelve Months as of date shown

    Market Drivers

    5/31/2026 to 9/20/2026
    ReturnCorrelation
    RNTX-27.9% 
    Market (SPY)0.9%41.3%
    Sector (XLV)12.7%2.9%

    Fundamental Drivers

    The -29.8% change in RNTX stock from 2/28/2026 to 9/20/2026 was primarily driven by a -60.7% change in the company's Shares Outstanding (Mil).
    (LTM values as of)22820269202026Change
    Stock Price ($)1.140.80-29.8%
    Change Contribution By: 
    Total Revenues ($ Mil)000.0%
    P/S Multiple∞∞0.0%
    Shares Outstanding (Mil)2667-60.7%
    Cumulative Contribution0.0%

    LTM = Last Twelve Months as of date shown

    Market Drivers

    2/28/2026 to 9/20/2026
    ReturnCorrelation
    RNTX-29.8% 
    Market (SPY)11.6%31.6%
    Sector (XLV)5.5%12.1%

    Fundamental Drivers

    The -42.4% change in RNTX stock from 8/31/2025 to 9/20/2026 was primarily driven by a -63.9% change in the company's Shares Outstanding (Mil).
    (LTM values as of)83120259202026Change
    Stock Price ($)1.390.80-42.4%
    Change Contribution By: 
    Total Revenues ($ Mil)000.0%
    P/S Multiple∞∞0.0%
    Shares Outstanding (Mil)2467-63.9%
    Cumulative Contribution0.0%

    LTM = Last Twelve Months as of date shown

    Market Drivers

    8/31/2025 to 9/20/2026
    ReturnCorrelation
    RNTX-42.4% 
    Market (SPY)19.4%25.8%
    Sector (XLV)24.1%4.0%

    Fundamental Drivers

    The -51.8% change in RNTX stock from 8/31/2023 to 9/20/2026 was primarily driven by a -93.2% change in the company's Shares Outstanding (Mil).
    (LTM values as of)83120239202026Change
    Stock Price ($)1.660.80-51.8%
    Change Contribution By: 
    Total Revenues ($ Mil)000.0%
    P/S Multiple∞∞0.0%
    Shares Outstanding (Mil)567-93.2%
    Cumulative Contribution0.0%

    LTM = Last Twelve Months as of date shown

    Market Drivers

    8/31/2023 to 9/20/2026
    ReturnCorrelation
    RNTX-51.8% 
    Market (SPY)75.6%12.9%
    Sector (XLV)32.3%2.5%

    Return vs. Risk

    Price Returns Compared

     202120222023202420252026Total [1]
    Returns
    RNTX Return-46%-79%29%-25%-50%-32%-96%
    Peers Return-6%19%17%39%35%-21%96%
    S&P 500 Return27%-19%24%23%16%12%103%

    Monthly Win Rates [3]
    RNTX Win Rate33%17%50%50%42%56% 
    Peers Win Rate42%52%46%44%59%44% 
    S&P 500 Win Rate75%42%67%75%67%44% 

    Max Drawdowns [4]
    RNTX Max Drawdown-77%-86%-64%-76%-60%-63% 
    Peers Max Drawdown-41%-38%-32%-28%-43%-40% 
    S&P 500 Max Drawdown-5%-25%-10%-8%-19%-9% 

    [1] Cumulative total returns since the beginning of 2021
    [2] Peers: UTHR, VRTX, INSM, PLRX, SION.
    [3] Win Rate = % of calendar months in which monthly returns were positive
    [4] Max drawdown represents maximum peak-to-trough decline within a year
    [5] 2026 data is for the year up to 9/18/2026 (YTD)

    How Low Can It Go

    EventRNTXS&P 500
    2024 Yen Carry Trade Unwind
      % Loss-46.1%-7.8%
      % Gain to Breakeven85.5%8.5%
      Time to Breakeven36 days18 days
    Summer-Fall 2023 Five Percent Yield Shock
      % Loss-38.2%-9.5%
      % Gain to Breakeven61.7%10.5%
      Time to Breakeven15 days24 days
    2023 SVB Regional Banking Crisis
      % Loss-49.1%-6.7%
      % Gain to Breakeven96.4%7.1%
      Time to Breakeven241 days31 days
    2020 COVID-19 Crash
      % Loss-58.5%-33.7%
      % Gain to Breakeven141.0%50.9%
      Time to Breakeven57 days140 days

    Compare to UTHR, VRTX, INSM, PLRX, SION

    In The Past

    Rein Therapeutics's stock fell -46.1% during the 2024 Yen Carry Trade Unwind. Such a loss loss requires a 85.5% gain to breakeven.

    Preserve Wealth

    Limiting losses and compounding gains is essential to preserving wealth.

    Asset Allocation

    Actively managed asset allocation strategies protect wealth. Learn more.

    EventRNTXS&P 500
    2024 Yen Carry Trade Unwind
      % Loss-46.1%-7.8%
      % Gain to Breakeven85.5%8.5%
      Time to Breakeven36 days18 days
    Summer-Fall 2023 Five Percent Yield Shock
      % Loss-38.2%-9.5%
      % Gain to Breakeven61.7%10.5%
      Time to Breakeven15 days24 days
    2023 SVB Regional Banking Crisis
      % Loss-49.1%-6.7%
      % Gain to Breakeven96.4%7.1%
      Time to Breakeven241 days31 days
    2020 COVID-19 Crash
      % Loss-58.5%-33.7%
      % Gain to Breakeven141.0%50.9%
      Time to Breakeven57 days140 days

    Compare to UTHR, VRTX, INSM, PLRX, SION

    In The Past

    Rein Therapeutics's stock fell -46.1% during the 2024 Yen Carry Trade Unwind. Such a loss loss requires a 85.5% gain to breakeven.

    Preserve Wealth

    Limiting losses and compounding gains is essential to preserving wealth.

    Asset Allocation

    Actively managed asset allocation strategies protect wealth. Learn more.

    About Rein Therapeutics (RNTX)

    ```html

    Rein Therapeutics Inc. (RNTX) is a biopharmaceutical company primarily focused on the development of innovative medicines. The company's strategic mission is to address significant unmet medical needs within highly specialized disease areas, specifically orphan pulmonary and various fibrosis indications.

    The core business of Rein Therapeutics revolves around the research, development, and eventual commercialization of therapeutic solutions for these challenging conditions. While the company's specific product pipeline is not detailed in the general description, their activities involve the rigorous process of drug discovery and clinical development aimed at producing novel treatments for diseases such as rare lung disorders and fibrotic conditions.

    Rein Therapeutics' primary market consists of patients suffering from these orphan pulmonary and fibrotic diseases, as well as the healthcare providers and medical institutions that serve them. By focusing on these underserved areas, the company aims to provide new and effective treatment options to patient populations who often have limited or no existing therapies.

    ```

    AI Analysis | Feedback

    ```html

    Here are 1-3 brief analogies for Rein Therapeutics (RNTX):

    • Vertex Pharmaceuticals for rare lung and fibrosis diseases
    • Alexion Pharmaceuticals for pulmonary fibrosis conditions
    ```

    AI Analysis | Feedback

    null

    AI Analysis | Feedback

    Rein Therapeutics Inc. (RNTX) is a biopharmaceutical company focused on developing medicines. As such, it sells its products primarily to other companies and institutions within the healthcare supply chain, rather than directly to individuals. While specific "major customers" (i.e., individual companies accounting for a significant portion of revenue) are typically not disclosed by biopharmaceutical companies unless they involve large licensing deals, the primary purchasers of medicines from manufacturers generally fall into the following categories:

    Rein Therapeutics' primary customers are typically:

    • Pharmaceutical Wholesalers and Distributors: These companies purchase medicines in bulk from manufacturers and distribute them to pharmacies, hospitals, and other healthcare providers. Examples of major public pharmaceutical wholesalers include:
      • McKesson Corp (MCK)
      • AmerisourceBergen Corp (ABC)
      • Cardinal Health Inc (CAH)
    • Hospitals and Health Systems: These institutions administer or dispense medicines directly to patients. While often purchasing through wholesalers, they are key end-customers in the institutional setting.
    • Specialty Pharmacies: For medicines addressing orphan diseases or complex conditions, distribution often occurs through a network of specialty pharmacies that provide specialized handling, dispensing, and patient support services.

    AI Analysis | Feedback

    null

    AI Analysis | Feedback

    Brian Windsor, Ph.D. President and CEO
    Dr. Windsor was appointed President and Chief Executive Officer of Rein Therapeutics in March 2024. Prior to this, he served as President and Chief Operating Officer of Aileron Therapeutics (Rein Therapeutics' former name) starting in October 2023. Dr. Windsor previously held the roles of President, Chief Executive Officer, and Director of Lung Therapeutics, Inc. from July 2013 until its acquisition by Aileron in October 2023. He also served as a director and Chief Science Officer for TFF Pharmaceuticals, Inc. (Nasdaq: TFFP) from September 2019 to March 2022, a public biopharmaceutical company that Lung Therapeutics spun out. Earlier in his career, Dr. Windsor was President of Enavail, LLC, a specialty pharmaceutical manufacturing company, from November 2009 to March 2013, overseeing all aspects of pharmaceutical drug development. He also directed portfolio company management for Emergent Technologies, Inc., an early-stage technology venture creation and management company, where he served as Managing Director or President for ten portfolio companies. Dr. Windsor holds a Ph.D. in Molecular Biology from The University of Texas at Austin.

    Timothy Cunningham, CPA, MBA Interim Chief Financial Officer
    Mr. Cunningham has served as Interim Chief Financial Officer (Principal Financial Officer) of Rein Therapeutics since May 2024 and is engaged via Danforth Advisors. He holds an MBA from Boston University and a B.S. in Accounting from Boston College and is a CPA in Florida. His extensive financial leadership experience includes serving as Chief Financial Officer for Neuphoria Therapeutics, Inc. since May 2023. Previously, he was Acting Chief Financial Officer for Peak Bio, Inc. from September 2022 to January 2024 and for SAB Biotherapeutics, Inc. from October 2020 to December 2021. Mr. Cunningham also served as Chief Financial Officer at Organogenesis from July 2016 to August 2020.

    Cory Hogaboam, Ph.D. Chief Scientific Officer
    Dr. Hogaboam serves as the Chief Scientific Officer of Rein Therapeutics.

    Kristie Lauterbach VP, Quality Assurance
    Ms. Lauterbach is the Vice President of Quality Assurance at Rein Therapeutics.

    Matt Karpen VP, CMC
    Mr. Karpen holds the position of Vice President of CMC (Chemistry, Manufacturing, and Controls) at Rein Therapeutics.

    AI Analysis | Feedback

    Key Risks to Rein Therapeutics (RNTX)

    1. Drug Development and Regulatory Risk: As a clinical-stage biopharmaceutical company, Rein Therapeutics' success hinges on the successful outcome and timely completion of its clinical trials and subsequent regulatory approvals. The company's RENEW Phase 2 clinical trial for LTI-03, targeting idiopathic pulmonary fibrosis, has experienced a clinical hold, introducing uncertainty regarding its timing and the actions required to resolve it. There is an inherent risk that early preclinical or clinical results may not be replicated in later trials, or that trials may not commence, continue, or be completed on time or at all due to enrollment and execution challenges. Furthermore, the integration of new technologies, such as Qureight's deep-learning platform, introduces additional execution and regulatory acceptance risks.
    2. Financial Viability and Funding Risk: Rein Therapeutics currently generates no revenue, which is typical for a clinical-stage company, and has reported significant losses and negative financial metrics like Earnings per Share, Return on Equity, and Return on Assets. The company's ability to continue operations and fund its ongoing and future clinical trials, including the RENEW Phase 2 trial, is dependent on securing additional cash resources. Delays in clinical trials, particularly due to regulatory issues, could further strain existing cash resources and necessitate additional financing, which may not be available on favorable terms or at all. The company has been noted for having a limited cash runway.

    AI Analysis | Feedback

    null

    AI Analysis | Feedback

    Rein Therapeutics' primary product candidate, LTI-03, targets Idiopathic Pulmonary Fibrosis (IPF). The global addressable market for Idiopathic Pulmonary Fibrosis was approximately USD 3.3 billion in 2023. This market is projected to grow, with estimates reaching USD 6.91 billion by 2034. Another report indicates the market size was USD 4.15 billion in 2024, is projected to reach USD 4.39 billion in 2025, and is expected to grow to USD 5.74 billion in 2029. North America represents a significant portion of the global IPF market, holding approximately 37.80% of the market share in 2025. The United States specifically accounts for the largest patient pool and market for IPF.

    For Rein Therapeutics' other product candidates, such as LTI-01 for loculated pleural effusions (LPE), and preclinical programs targeting cystic fibrosis and systemic fibrosis indications, the addressable market sizes are currently unavailable in the provided information.

    AI Analysis | Feedback

    Here are 3-5 expected drivers of future revenue growth for Rein Therapeutics (RNTX) over the next 2-3 years:

    1. Successful Clinical Development and Commercialization of LTI-03 for Idiopathic Pulmonary Fibrosis (IPF): Rein Therapeutics' lead asset, LTI-03, is currently in a Phase 2 clinical trial for the treatment of IPF, with initial data anticipated in the latter half of 2026 and patient enrollment continuing until mid-2027. The successful progression through clinical trials, regulatory approval, and subsequent market launch of LTI-03 would be the primary driver of future revenue, addressing a condition with limited therapeutic options.
    2. Advancement of LTI-01 for Loculated Pleural Effusion: Rein Therapeutics also has LTI-01, a proenzyme for loculated pleural effusion, as another Phase 2-ready clinical asset. The successful clinical development and potential commercialization of LTI-01 could contribute to future revenue growth, especially given that loculated pleural effusion currently has no approved drug treatment.
    3. Pipeline Expansion and New Indications: While LTI-03 and LTI-01 are the immediate focus, successful development of these lead candidates could enable Rein Therapeutics to expand its pipeline with new product candidates or pursue additional indications for its existing drugs. This strategic expansion into other orphan pulmonary and fibrosis indications would open up new market opportunities and diversify potential revenue streams in the medium to long term.

    AI Analysis | Feedback

    Share Issuance

    • Rein Therapeutics received approximately $5.28 million in aggregate gross proceeds from warrant exercise and exchange transactions and a simultaneous private placement in April 2025.
    • The company filed a shelf registration statement in May 2025 to offer and sell up to $150 million in aggregate offering price of securities, including up to $15,773,673 of common stock under a sales agreement.
    • In February 2026, Rein Therapeutics entered into securities purchase agreements for a private placement of unsecured promissory notes totaling $2.3 million in aggregate purchase price from three institutional investors.

    Inbound Investments

    • Rein Therapeutics secured approximately $5.28 million in April 2025 through warrant exercises, exchanges, and a private placement, which included participation from an entity affiliated with Bios Equity Partners, LP.
    • In July 2025, the company entered into a $6 million pre-paid advance agreement with an affiliate of Yorkville Advisors Global, LP, with an initial $1 million advance funded at signing. The company later secured a third $1 million advance under this agreement by December 2025.
    • As of March 2026, institutional investors bought a total of 9,091,295 shares of Rein Therapeutics in the preceding 24 months, representing approximately $11.71 million in transactions.

    Capital Expenditures

    • Rein Therapeutics reported $0 in capital expenditures in Q4 2021.
    • The company indicated in Q1 2025 that its cash and cash equivalents, combined with proceeds from April 2025 transactions, were expected to fund planned operating expenses and capital expenditure requirements through September 2025.
    • Investment activities generally provide weak support for research and development spending, suggesting potentially insufficient capital expenditure for innovation relative to other capital deployments.

    Peer Outperformance in Biotechnology

    RNTX has trailed 75% of its 363 Biotechnology peers over 5Y. Biotechnology ranks 10th of 10 industries in Health Care by median 5Y return. The sector’s gains have largely come from elsewhere.
    Share of Biotechnology constituents that RNTX has outperformed, by holding period. Peers without a full price history over a given window are excluded from that window.
    1Y
    32%
    of 455 industry peers · -33.9% return
    3Y
    41%
    of 402 industry peers · -48.0% return
    5Y
    25%
    of 363 industry peers · -96.3% return
    null
    Median price return by industry across the Health Care sector, ranked by 5Y. Biotechnology is RNTX's own industry. Use this to see which corners of the sector have carried the returns.
    Industry Names 1Y med3Y med5Y med Top 3 by 5Y
    Health Care Distributors 6 16.2%43.2%90.1% CAH 392% · MCK 346% · COR 168%
    Managed Health Care 8 40.4%-5.3%2.3% OSCR 84% · HQY 56% · ELV 17%
    Health Care Services 20 21.1%37.6%-0.3% HIMS 239% · RDNT 173% · DGX 76%
    Health Care Facilities 24 6.0%6.5%-4.5% NHC 271% · THC 261% · ENSG 129%
    Health Care Equipment 50 -2.7%-0.2%-21.1% POCI 11050% · UFPT 341% · GKOS 222%
    Pharmaceuticals 62 -10.5%14.8%-38.6% LQDA 2472% · INDV 1099% · ETON 1051%
    Health Care Supplies 12 14.1%-8.9%-39.7% LNTH 287% · HAE 54% · MMSI 20%
    Life Sciences Tools & Services 109 4.3%-11.3%-68.4% SNWV 1757% · MEDP 231% · NTRA 199%
    Health Care Technology 21 -25.8%-52.6%-79.2% SPOK 68% · HSTM 3% · VEEV -13%
    Biotechnology ← 364 0.6%-21.7%-79.4% CELZ 1280% · DNTH 1221% · ELVN 1069%
    Median of constituents with a full price history over each window. Top names are unfiltered by size in this render.

    Recent Active Movers

    Top Gainers

    TickerCompanyMkt Cap (B)1W RtnYTD Rtn
    SDGRSchrodinger2.252.6%62.3%
    PSPershing Square19.932.3%106.6%
    BBNXBeta Bionics1.032.1%-28.2%
    TEMTempus AI14.031.9%31.8%
    SECZSecuritize1.631.3%-11.7%
    TWSTTwist Bioscience10.431.3%426.5%
    EMATEvolution Metals & Technologies2.530.5%-81.1%
    GEMIGemini Space Station0.730.3%-41.4%
    RUMRumble2.626.8%43.8%
    ALMRAlamar Biosciences2.025.0%58.4%

    Top Losers

    TickerCompanyMkt Cap (B)1W RtnYTD Rtn
    ADBTAdvasa0.1-47.1%-98.0%
    SWMRSwarmer0.4-39.4%-22.6%
    ALHCAlignment Healthcare1.7-33.8%-57.7%
    XENEXenon Pharmaceuticals4.0-32.2%-11.3%
    FLNCFluence Energy1.0-26.3%-63.0%
    ENVAEnova International4.3-21.8%11.1%
    VYXNCR Voyix0.9-21.2%-33.9%
    ARWRArrowhead Pharmaceuticals9.5-19.8%0.1%
    DMRADamora Therapeutics1.4-19.6%-1.8%
    IONSIonis Pharmaceuticals7.4-18.0%-43.8%

    Top Gainers

    TickerCompanyMkt Cap (B)1M RtnYTD Rtn
    SECZSecuritize1.680.1%-11.7%
    FWDIForward Industries0.755.9%16.5%
    PURRHyperliquid Strategies1.750.1%295.8%
    GEMIGemini Space Station0.747.8%-41.4%
    MSTRStrategy54.347.6%1.3%
    SMTCSemtech17.247.6%151.1%
    CVICVR Energy5.446.3%112.4%
    SDGRSchrodinger2.246.2%62.3%
    EMATEvolution Metals & Technologies2.541.1%-81.1%
    ACVAACV Auctions1.840.3%30.7%

    Top Losers

    TickerCompanyMkt Cap (B)1M RtnYTD Rtn
    ALMSAlumis1.0-67.6%-20.4%
    IESCIES12.8-47.5%-17.2%
    SWMRSwarmer0.4-46.9%-22.6%
    RAREUltragenyx Pharmaceutical1.5-44.7%-36.9%
    TTANServiceTitan5.2-42.1%-48.3%
    FLNCFluence Energy1.0-39.4%-63.0%
    KRMNKarman4.7-38.6%-51.1%
    XENEXenon Pharmaceuticals4.0-36.2%-11.3%
    DYNDyne Therapeutics2.8-36.1%-12.5%
    DKSDick's Sporting Goods10.7-36.1%-37.5%

    More From Trefis

    Research & Analysis

    Invest in Strategies

    Wealth Management

    Peer Comparisons

    Peers to compare with:

    Financials

    RNTXUTHRVRTXINSMPLRXSIONMedian
    NameRein The.United T.Vertex P.Insmed Pliant T.Sionna T. 
    Mkt Price0.80494.63508.34120.001.115.9662.98
    Mkt Cap0.121.1129.026.10.10.310.7
    Rev LTM03,15412,5871,13800569
    Op Inc LTM-211,4034,777-813-97-109-59
    FCF LTM-191,0883,796-808-71-76-45
    FCF 3Y Avg-221,0121,957-756-127--22
    CFO LTM-191,6854,293-779-71-76-45
    CFO 3Y Avg-221,3872,398-733-126--22

    Growth & Margins

    RNTXUTHRVRTXINSMPLRXSIONMedian
    NameRein The.United T.Vertex P.Insmed Pliant T.Sionna T. 
    Rev Chg LTM-2.5%10.2%185.8%--10.2%
    Rev Chg 3Y Avg-14.7%9.8%76.3%--14.7%
    Rev Chg Q--1.9%12.5%296.1%--12.5%
    QoQ Delta Rev Chg LTM--0.5%3.0%38.8%--3.0%
    Op Inc Chg LTM14.7%-8.9%2,497.9%12.4%55.7%-24.9%13.6%
    Op Inc Chg 3Y Avg-9.5%9.7%792.2%-10.0%6.3%-6.3%
    Op Mgn LTM-44.5%37.9%-71.4%--37.9%
    Op Mgn 3Y Avg-47.6%23.9%-166.8%--23.9%
    QoQ Delta Op Mgn LTM--1.5%-0.2%46.3%---0.2%
    CFO/Rev LTM-53.4%34.1%-68.5%--34.1%
    CFO/Rev 3Y Avg-46.7%19.6%-151.8%--19.6%
    FCF/Rev LTM-34.5%30.2%-71.0%--30.2%
    FCF/Rev 3Y Avg-34.3%15.7%-156.3%--15.7%

    Valuation

    RNTXUTHRVRTXINSMPLRXSIONMedian
    NameRein The.United T.Vertex P.Insmed Pliant T.Sionna T. 
    Mkt Cap0.121.1129.026.10.10.310.7
    P/S-6.710.222.9--10.2
    P/Op Inc-2.615.027.0-32.1-0.7-2.5-1.6
    P/EBIT-2.613.325.6-32.9-0.8-2.5-1.6
    P/E-1.116.129.3-29.8-0.7-2.8-0.9
    P/CFO-2.812.530.0-33.5-1.0-3.5-1.9
    Total Yield-92.7%6.2%3.4%-3.4%-134.3%-36.2%-19.8%
    Dividend Yield0.0%0.0%0.0%0.0%0.0%0.0%0.0%
    FCF Yield 3Y Avg-45.4%6.4%1.6%-4.6%-120.6%--4.6%
    D/E0.00.00.00.00.40.00.0
    Net D/E-0.8-0.1-0.0-0.0-1.9-0.8-0.4

    Returns

    RNTXUTHRVRTXINSMPLRXSIONMedian
    NameRein The.United T.Vertex P.Insmed Pliant T.Sionna T. 
    1M Rtn-2.2%-3.6%-7.2%-4.6%-3.9%12.7%-3.7%
    3M Rtn-12.6%-7.8%12.6%25.3%-4.3%-84.0%-6.1%
    6M Rtn-35.5%-5.7%12.0%-11.8%-14.0%-83.6%-12.9%
    12M Rtn-33.9%18.5%32.7%-17.1%-22.4%-74.2%-19.7%
    3Y Rtn-48.0%121.1%43.5%355.6%-93.0%-76.2%-2.3%
    1M Excs Rtn1.8%-5.8%-7.2%-7.4%-4.4%-3.9%-5.1%
    3M Excs Rtn-14.6%-9.8%10.6%23.3%-6.3%-86.0%-8.1%
    6M Excs Rtn-54.3%-21.9%-4.8%-32.5%-32.3%-99.0%-32.4%
    12M Excs Rtn-46.3%6.6%15.4%-33.0%-39.9%-89.1%-36.5%
    3Y Excs Rtn-121.3%51.2%-24.7%285.0%-164.5%-147.4%-73.0%

    Comparison Analyses

    null

    Financials

    $ Mil | FY: 12/312026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q32024Q22024Q12023Q42023Q3
    Period End6/30/20263/31/202612/31/20259/30/20256/30/20253/31/202512/31/20249/30/20246/30/20243/31/202412/31/20239/30/2023
    Filing Date8/14/20265/15/20263/26/202611/14/20258/14/20255/15/20254/7/202511/14/20248/14/20245/15/20244/15/202410/13/2023
    Key Financials Quarterly            
    Total Revenue000000000000
    Ebitda-6-5-4-5-7-6-6-6-9-7-7-2
    Operating Income-6-5-4-5-7-6-6-6-9-7-7-2
    Net Income-6-6-32-6-7-6-41-6-9-7-7-2
    EPS-0.10-0.19-1.22-0.21-0.28-0.25-2.20-0.27-0.45-0.86-1.57-0.40
    Key Financials TTM            
    Total Revenue TTM000000000000
    Ebitda TTM-21-22-22-24-24-27-28-30-25-18-15-13
    Operating Income TTM-21-22-22-24-24-27-28-30-26-19-15-13
    Net Income TTM-50-50-50-59-59-61-63-29-25-18-16-13
    Growth Rates Quarterly            
    Total Revenue Growth------------
    EBITDA Growth11.6%6.8%31.7%9.5%24.0%21.5%20.0%-209.0%-336.9%-81.1%-55.6%69.5%
    Operating Income Growth11.6%6.8%31.7%9.5%24.0%22.2%20.6%-207.1%-334.6%-80.6%-55.3%69.5%
    Net Income Growth6.6%-6.1%22.0%4.5%23.7%22.7%-458.4%-220.0%-400.4%-48.8%-61.4%71.3%
    Margins Quarterly            
    EBITDA Margin------------
    Operating Income Margin------------
    Net Income Margin------------
    Cash & Debt            
    Total Cash4143467131822121712
    Total Debt050000000000
    Net Debt / (Cash)-410-3-4-6-7-13-18-22-12-17-12
    Cash Flows Quarterly            
    FCF from Operations-9-3-3-4-6-6-5-4-8-5-10-2
    Cash Flows TTM            
    FCF from Operations TTM-19-17-19-21-21-23-22-28-26-20-20-14
    Returns to Shareholders Quarterly            
    Dividends000000000000
    Share Repurchases-0-0-0-0-0-0-0-0-0-0-0-0
    Return on Invested Capital (ROIC) Quarterly            
    ROIC-6.3%-5.6%-4.3%-6.0%-7.6%-6.3%-6.7%-7.1%-10.7%-8.8%-10.5%-2.8%
    Return on Invested Capital (ROIC) TTM            
    ROIC TTM-5.4%-5.8%-5.9%-6.5%-6.7%-7.5%-8.1%-8.6%-7.5%-5.7%-5.5%-4.5%

    Segment Financials

    Revenue by Segment
    $ Mil2025202420232022
    Developing novel therapies for the treatment of orphan pulmonary and fibrosis indications with no0000
    Total0000


    Net Income by Segment
    $ Mil202520242023
    Developing novel therapies for the treatment of orphan pulmonary and fibrosis indications with no-50-63-16
    Total-50-63-16


    Assets by Segment
    $ Mil20232022202120202019
    Developing novel therapies for the treatment of orphan pulmonary and fibrosis indications with no10622481626
    Total10622481626


    Price Behavior

    Price Behavior
    Market Price$0.80 
    Market Cap ($ Bil)0.1 
    First Trading Date06/29/2017 
    Distance from 52W High-57.4% 
       50 Days200 Days
    DMA Price$0.81$1.13
    DMA Trenddowndown
    Distance from DMA-0.8%-29.4%
     3M1YR
    Volatility73.8%87.1%
    Downside Capture313.77280.91
    Upside Capture211.35185.94
    Correlation (SPY)39.7%27.6%
    RNTX Betas & Captures as of 8/31/2026

     1M2M3M6M1Y3Y
    Beta1.172.261.731.701.630.97
    Up Beta0.731.362.021.631.030.52
    Down Beta3.832.541.421.181.370.11
    Up Capture112%134%80%118%153%241%
    Bmk +ve Days10213268138427
    Stock +ve Days10192857106324
    Down Capture145%370%241%202%168%112%
    Bmk -ve Days11213259113324
    Stock -ve Days9213160126384

    [1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
    Based On 1-Year Data
    Annualized
    Return    		Annualized
    Volatility    		Sharpe
    Ratio    		Correlation
    with RNTX
    RNTX-30.5%86.8%-0.04-
    Sector ETF (XLV)24.4%16.1%1.164.8%
    Equity (SPY)16.9%12.9%0.9427.6%
    Gold (GLD)19.1%29.3%0.6022.7%
    Commodities (DBC)46.3%20.6%1.73-3.3%
    Real Estate (VNQ)4.9%13.6%0.104.3%
    Bitcoin (BTCUSD)-30.6%44.3%-0.7021.6%

    Smart multi-asset allocation framework can stack odds in your favor. Learn How
    Based On 5-Year Data
    Annualized
    Return    		Annualized
    Volatility    		Sharpe
    Ratio    		Correlation
    with RNTX
    RNTX-49.9%110.6%-0.16-
    Sector ETF (XLV)6.4%15.2%0.247.2%
    Equity (SPY)12.9%17.2%0.5716.6%
    Gold (GLD)19.1%18.8%0.839.2%
    Commodities (DBC)11.2%19.5%0.457.0%
    Real Estate (VNQ)1.1%18.8%-0.0511.7%
    Bitcoin (BTCUSD)12.5%52.5%0.4210.6%

    Smart multi-asset allocation framework can stack odds in your favor. Learn How
    Based On 10-Year Data
    Annualized
    Return    		Annualized
    Volatility    		Sharpe
    Ratio    		Correlation
    with RNTX
    RNTX-42.9%110.7%-0.07-
    Sector ETF (XLV)10.6%16.7%0.5112.0%
    Equity (SPY)15.1%18.0%0.7217.3%
    Gold (GLD)12.1%16.4%0.618.5%
    Commodities (DBC)8.3%18.1%0.3711.0%
    Real Estate (VNQ)4.4%20.7%0.1811.8%
    Bitcoin (BTCUSD)62.6%66.2%1.025.2%

    Smart multi-asset allocation framework can stack odds in your favor. Learn How

    Short Interest

    Short Interest: As Of Date8312026
    Short Interest: Shares Quantity0.6 Mil
    Short Interest: % Change Since 8152026-12.6%
    Average Daily Volume0.5 Mil
    Days-to-Cover Short Interest1.2 days
    Basic Shares Quantity67.1 Mil
    Short % of Basic Shares1.0%

    Earnings Returns History

    Updated 9/4/2026
    Expand for More
     Forward Returns
    Earnings Date1D Returns5D Returns21D Returns
    5/15/2025-6.4%-17.8%-22.9%
    11/14/2024-13.3%-22.1%-36.0%
    8/14/2024-10.8%38.4%48.1%
    5/15/2024-1.3%-5.1%-17.4%
    SUMMARY STATS   
    # Positive011
    # Negative433
    Median Positive 38.4%48.1%
    Median Negative-8.6%-17.8%-22.9%
    Max Positive 38.4%48.1%
    Max Negative-13.3%-22.1%-36.0%
     Collapse to Preview
     Forward Returns
    Earnings Date1D Returns5D Returns21D Returns
    5/15/2025-6.4%-17.8%-22.9%
    11/14/2024-13.3%-22.1%-36.0%
    8/14/2024-10.8%38.4%48.1%
    5/15/2024-1.3%-5.1%-17.4%
    SUMMARY STATS   
    # Positive011
    # Negative433
    Median Positive 38.4%48.1%
    Median Negative-8.6%-17.8%-22.9%
    Max Positive 38.4%48.1%
    Max Negative-13.3%-22.1%-36.0%

    SEC Filings

    Expand for More
    Report DateFiling DateFiling
    06/30/202608/14/202610-Q
    03/31/202605/15/202610-Q
    12/31/202503/26/202610-K
    09/30/202511/14/202510-Q
    06/30/202508/14/202510-Q
    03/31/202505/15/202510-Q
    12/31/202404/07/202510-K
    09/30/202411/14/202410-Q
    06/30/202408/14/202410-Q
    03/31/202405/15/202410-Q
    12/31/202304/15/202410-K
    09/30/202310/13/202310-Q
    06/30/202308/11/202310-Q
    03/31/202305/08/202310-Q
    12/31/202203/20/202310-K
    09/30/202211/01/202210-Q
     Collapse to Preview
    Report DateFiling DateFiling
    06/30/202608/14/202610-Q
    03/31/202605/15/202610-Q
    12/31/202503/26/202610-K
    09/30/202511/14/202510-Q
    06/30/202508/14/202510-Q
    03/31/202505/15/202510-Q
    12/31/202404/07/202510-K
    09/30/202411/14/202410-Q
    06/30/202408/14/202410-Q
    03/31/202405/15/202410-Q
    12/31/202304/15/202410-K
    09/30/202310/13/202310-Q
    06/30/202308/11/202310-Q
    03/31/202305/08/202310-Q
    12/31/202203/20/202310-K
    09/30/202211/01/202210-Q
    06/30/202208/15/202210-Q
    03/31/202205/05/202210-Q
    12/31/202103/28/202210-K
    09/30/202111/12/202110-Q
    06/30/202108/11/202110-Q
    03/31/202105/11/202110-Q
    12/31/202003/24/202110-K
    09/30/202011/12/202010-Q
    06/30/202008/05/202010-Q
    03/31/202005/11/202010-Q
    12/31/201903/30/202010-K
    09/30/201911/07/201910-Q

    Insider Activity

    Updated 5/28/2026
    Expand for More
    #OwnerTitleHoldingActionFiling DatePriceSharesTransacted
    Value    		Value of
    Held Shares    		Form
    1Von, Rickenbach Josef H DirectBuy52720261.074,5004,81966,940Form
    2Von, Rickenbach Josef H DirectBuy52720261.0623,19024,47061,216Form
    3Von, Rickenbach Josef H DirectBuy52720261.0515,95016,70836,478Form
    4Von, Rickenbach Josef H DirectBuy52720261.043,4203,56419,670Form
    5Windsor, James BrianSee RemarksDirectBuy51220261.0025,00025,00027,046Form
     Collapse to Preview
    #OwnerTitleHoldingActionFiling DatePriceSharesTransacted
    Value    		Value of
    Held Shares    		Form
    1Von, Rickenbach Josef H DirectBuy52720261.074,5004,81966,940Form
    2Von, Rickenbach Josef H DirectBuy52720261.0623,19024,47061,216Form
    3Von, Rickenbach Josef H DirectBuy52720261.0515,95016,70836,478Form
    4Von, Rickenbach Josef H DirectBuy52720261.043,4203,56419,670Form
    5Windsor, James BrianSee RemarksDirectBuy51220261.0025,00025,00027,046Form
    6Voss, Capital, LPBy: Voss Value Master Fund, L.P.Buy111820251.22104,183127,5931,134,612Form
    7Voss, Capital, LPBy: Voss Value-Oriented Special Situations Fund, L.P.Buy102820251.39178,392247,965695,000Form
    8Voss, Capital, LPBy: Voss Value Master Fund, L.P.Buy102820251.3792,642126,9201,126,493Form
    9Voss, Capital, LPBy: Voss Value-Oriented Special Situations Fund, L.P.Buy102820251.374,8406,625440,185Form
    10Voss, Capital, LPBy: Voss Value Master Fund, L.P.Buy102820251.3930,17641,9571,014,458Form

    Investor Activity (13F)

    Updated Sep 21, 2026
    13F holdings as of Mar 31, 2026 (Q1 2026)

    Active managers (13F portfolio over $250M, at least 3 holdings) with a position over $5M that is either over 10% of their portfolio or held in a concentrated book of 50 or fewer total positions. Index/ETF, sovereign, bank, community-bank and charitable/donor-advised filers are excluded.

    Active ManagerValue% of PortfolioTotal PositionsQoQFiling
    Voss Capital, LP$5.7 Mil0.3%39Hold13F
    Active Manager
    Active Manager
    Active ManagerValue% of PortfolioTotal PositionsQoQFiling
    Voss Capital, LP$5.7 Mil0.3%39Hold13F

    Rein Therapeutics — Investor Video Playlist

    Industry Resources

    External Quote Links


    Prefer one of these to Trefis? Tell us why.
    Core Cache Last Updated: 9/20/2026